Casey Tansey joined USVP as a General Partner in April of 2005. A veteran of the medical device industry, Casey brings over 30 years of entrepreneurial, early-stage medical device and seasoned operating experience to USVP. At USVP, Casey focuses on the trend toward miniaturization of devices and the development of minimally invasive technologies that promise innovations in the delivery of medical products and services, especially in cardiovascular products, sleep apnea, ENT and vascular.
Prior to joining USVP, Casey served as the CEO and President of Epicor Medical from 2001 to 2004. Casey, along with a dedicated team, pioneered a minimally invasive treatment for atrial fibrillation. He led Epicor’s acquisition by St. Jude Medical. Prior to Epicor, Casey was CEO and President of Heartport, a public company that helped pioneer minimally invasive cardiac surgery which is now a Johnson & Johnson company. Before that, he was with Baxter Edward’s Cardiovascular Division for nearly ten years, holding various sales and marketing positions. During his tenure at Baxter, Casey was involved in launching innovative heart valve products that have grown to be the market leaders.
Casey's notable board activities have included Inspire Medical (IPO), IntersectENT (IPO), AtheroMed (sold to Volcano), Nanostim (sold to St. Jude Medical), PlaceIQ (acquired by Precisely) and SentreHeart (sold to AtriCure). Currently, he serves on the Board of Directors for Dstillery, HeartFlow, Highlife Medical, Inspire Medical, Intuity Medical, NeoChord, Neuros Medical, Shiratronics, Shoulder Innovations and Standard Bariatrics. Casey also served as the Chairman of the Board of Directors of the World Heart Foundation, an organization dedicated to advancing humanitarian efforts in heart surgery worldwide through education and collaboration. Casey holds a B.S. and M.B.A. from the College of Notre Dame in Belmont, CA.